Apellis Pharmaceuticals, Inc. $APLS Shares Sold by Hsbc Holdings PLC

Hsbc Holdings PLC decreased its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 80.4% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 24,999 shares of the company’s stock after selling 102,829 shares during the period. Hsbc Holdings PLC’s holdings in Apellis Pharmaceuticals were worth $552,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Assetmark Inc. grew its holdings in Apellis Pharmaceuticals by 3,938.7% in the first quarter. Assetmark Inc. now owns 1,252 shares of the company’s stock valued at $27,000 after purchasing an additional 1,221 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of Apellis Pharmaceuticals during the fourth quarter valued at $83,000. Nomura Holdings Inc. acquired a new stake in shares of Apellis Pharmaceuticals during the fourth quarter valued at $223,000. Legacy Capital Group California Inc. boosted its stake in shares of Apellis Pharmaceuticals by 32.8% during the first quarter. Legacy Capital Group California Inc. now owns 9,554 shares of the company’s stock valued at $209,000 after acquiring an additional 2,359 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Apellis Pharmaceuticals by 19.6% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,615 shares of the company’s stock valued at $307,000 after acquiring an additional 1,578 shares during the last quarter. Institutional investors and hedge funds own 96.29% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently commented on APLS shares. Wall Street Zen raised Apellis Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, August 2nd. Wells Fargo & Company increased their price objective on Apellis Pharmaceuticals from $26.00 to $29.00 and gave the company an “equal weight” rating in a research note on Monday, June 2nd. Raymond James Financial decreased their price objective on Apellis Pharmaceuticals from $52.00 to $50.00 and set an “outperform” rating on the stock in a research note on Friday, August 1st. Robert W. Baird increased their price objective on Apellis Pharmaceuticals from $47.00 to $50.00 and gave the company an “outperform” rating in a research note on Friday, July 18th. Finally, Scotiabank decreased their price objective on Apellis Pharmaceuticals from $28.00 to $20.00 and set a “sector perform” rating on the stock in a research note on Thursday, May 8th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Apellis Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $34.12.

Apellis Pharmaceuticals Stock Down 1.7%

Shares of NASDAQ:APLS opened at $27.57 on Tuesday. The stock’s 50-day moving average price is $22.16 and its two-hundred day moving average price is $21.29. The company has a current ratio of 3.77, a quick ratio of 3.16 and a debt-to-equity ratio of 2.90. Apellis Pharmaceuticals, Inc. has a 12-month low of $16.10 and a 12-month high of $41.94. The firm has a market cap of $3.48 billion, a price-to-earnings ratio of -15.15 and a beta of 0.73.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings results on Thursday, July 31st. The company reported ($0.33) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.11. The firm had revenue of $171.39 million for the quarter, compared to analyst estimates of $187.91 million. Apellis Pharmaceuticals had a negative return on equity of 116.09% and a negative net margin of 30.24%.The firm’s quarterly revenue was down 10.6% on a year-over-year basis. During the same period last year, the company earned ($0.30) EPS. On average, research analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Insider Transactions at Apellis Pharmaceuticals

In other news, CEO Cedric Francois sold 175,037 shares of the firm’s stock in a transaction dated Wednesday, August 27th. The stock was sold at an average price of $28.19, for a total value of $4,934,293.03. Following the transaction, the chief executive officer directly owned 357,909 shares in the company, valued at $10,089,454.71. This trade represents a 32.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, General Counsel David O. Watson sold 5,000 shares of the firm’s stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $27.80, for a total value of $139,000.00. Following the completion of the transaction, the general counsel owned 123,730 shares in the company, valued at approximately $3,439,694. This trade represents a 3.88% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 399,090 shares of company stock worth $9,895,574. Company insiders own 6.80% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).